Riskpilot← Back to searchSign inGet full accessEVOMED AB
ABActiveOrg 5569504227Vasserudsvägen 11Physiotherapy activities · NACE 8695Est. 20131-4 employees
Revenue 2024
SEK 2,1M
+8% vs 2023
EBITDA margin
6.6%
-13% vs 2023
Equity ratio
71.5%
Financial strength
Net profit 2024
SEK 90K
-17% vs 2023
| Revenue | SEK 2,1M | +8% |
| EBITDA | SEK 140K | -13% |
| Net profit | SEK 90K | -17% |
| Total assets | SEK 505K | -6% |
| Equity | SEK 361K | -14% |
| Employees | — | — |
Legal name
EVOMED AB
Org number
5569504227
Legal form
Aktiebolag
NACE code
8695 · Physiotherapy activities
Founded
26 november 2013
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska utföra frisk- och sjukvård, utbilda och föreläsa inom ämnet hälsa samt därmed förenlig verksamhet. Bolaget ska också bedriva handel och förvaltning av värdepapper.
Address
Vasserudsvägen 11
Email
jennyskilberg@evomed.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 931 | 2 642 | 2 178 | 1 982 | 2 134 |
| Staff expenses | — | — | −1 196 | −793 | −589 |
| EBITDA | 61 | 227 | −34 | 161 | 140 |
| Depreciation & amort. | −50 | −53 | −28 | −28 | −28 |
| EBIT | 11 | 174 | −62 | 133 | 112 |
| Net financials | −8 | −19 | −8 | 1 | 4 |
| Profit before tax | 30 | 115 | −29 | 134 | 116 |
| Tax | −8 | −25 | — | −25 | −26 |
| Net profit | 22 | 90 | −29 | 109 | 90 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 544 | 744 | 472 | 535 | 505 |
| Equity | 251 | 341 | 311 | 421 | 361 |
| Long-term debt | 111 | 82 | 0 | — | — |
| Short-term debt | 182 | 280 | 161 | 115 | 144 |
| Total debt | 293 | 362 | 161 | 115 | 144 |
EBITDA margin
6.6%
This company
15.8%
Market median
-58% vs market
20202024
Equity ratio
71.5%
This company
38.2%
Market median
+87% vs market
20202024
Return on equity
25.0%
This company
18.4%
Market median
+36% vs market
20202024
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20202024
Asset turnover
4.23×
This company
1.12×
Market median
+278% vs market
20202024
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JT Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EVOMED AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jenny Terese Skilberg | Chief Executive Officer | 0 companies |
| Lars David Mikael Skilberg | Deputy Board Member | 0 companies |